Publications by authors named "Larosa M"
The treatment landscape for Rheumatoid Arthritis (RA) has evolved significantly with the introduction of Janus kinase inhibitors (JAKi), such as Tofacitinib (TOFA), which offer a new therapeutic option for patients who have failed or are intolerant to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs). Safety concerns, particularly related to cardiovascular and cancer risks, prompted a need for additional investigation in real-world clinical settings. This study aimed to evaluate the long-term effectiveness and predictors of response to TOFA in two subpopulations of RA patients, categorized by differing cardiovascular risk profiles.
View Article and Find Full Text PDFBackground: Upadacitinib (UPA) is a selective, reversible Janus kinase inhibitor (JAKi) approved for the treatment of RA. However, there is still no solid evidence on the long-term efficacy of UPA in treated patients. The purpose of this study was to determine the efficacy of UPA to obtain remission or low disease activity (LDA) in a series of UPA patients in patients with RA after 6 and 12 months of treatment in a real-world setting.
View Article and Find Full Text PDFArticle Synopsis
- The Janus kinase inhibitors (JAKi) like tofacitinib, baricitinib, upadacitinib, and filgotinib are effective in treating rheumatoid arthritis but faced safety concerns from the FDA and EMA, particularly about serious adverse events (SAEs) such as thrombosis and cancer.
- The study aimed to analyze the impact of the EMA's first two safety warnings on how rheumatologists in Italy prescribed JAKi from July 2019 to June 2022, using data from 29 rheumatology centers.
- Results showed a significant reduction (32%) in JAKi prescriptions after the first warning, with a smaller decrease (16%) observed after the second warning, although there
Aim: To compare the effectiveness of different basal insulins (BI) prescribed as an add-on to or switch from glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy.
Materials And Methods: Retrospective, real-world data from electronic medical records of 32 Italian diabetes clinics were used, after propensity score adjustment, to compare effectiveness after 6 months of treatment with second- versus first-generation BI (2BI vs. 1BI) or glargine 300 U/ml versus degludec 100 U/ml (Gla-300 vs.
Objectives: Data about hydroxychloroquine (HCQ) levels during pregnancy are sparse. We assessed HCQ whole blood levels at first trimester of pregnancy as a potential predictor of maternal and obstetric/fetal outcomes in patients with systemic lupus erythematosus (SLE).
Methods: We included pregnant SLE patients enrolled in the prospective GR2 study receiving HCQ, with at least one available first-trimester whole-blood HCQ assay.
Aims: Glargine 300 U/mL (Gla-300) has been recently approved for use in children and adolescents with type 1 diabetes (T1D). However, real-world effectiveness data are scarce, and aim of this analysis was to assess clinical outcomes in young patients with T1D switching from 1st generation basal insulin (1BI) to Gla-300.
Methods: ISPED CARD is a retrospective, multicenter study, based on data anonymously extracted from Electronic Medical Records.
Article Synopsis
- This study compares the effectiveness of adding basal insulin (Gla-300) to existing GLP-1 receptor agonist therapy versus switching to a fixed combination (iDegLira) in diabetes patients in Italy.
- After 6 months, the group using Gla-300 showed greater improvements in fasting blood glucose and required a slight increase in insulin dosage compared to the iDegLira group, despite both groups achieving low insulin doses.
- The findings suggest that adding Gla-300 allows for better glucose control, potentially due to more effective insulin titration, although both groups faced challenges in starting and adjusting their insulin treatment.
Article Synopsis
- The study examined pregnancy outcomes in women with autoimmune rheumatic diseases (ARD) enrolled in the Italian P-RHEUM.it cohort from 2018 to 2023, focusing on maternal and infant health.
- Results showed that out of 866 pregnancies, 15.6% experienced maternal disease flares, 30.1% had obstetrical complications, and 91.7% resulted in live births, with a relatively low rate of perinatal deaths and complications.
- The research concluded that effective preconception counseling and proper medication management during pregnancy may help reduce disease-related risks, suggesting that outcomes for women with ARD were comparable to those in the general obstetric population.
This publication provides an overview of current imaging indications and practices for patients undergoing gender-affirming surgery, with an emphasis on the importance of tailored, patient-specific care. Gender-affirming surgeries are performed with personalized approaches at various stages of life for those with intersex traits or differences in sex development (I/DSD) and transgender and gender diverse (TGD) individuals. For I/DSD patients, ultrasound, genitography, or MRI occurs during infancy and puberty to evaluate genital and gonadal anatomy.
View Article and Find Full Text PDFArticle Synopsis
- The study explored the role of complement levels (C3 and C4) as potential biomarkers for monitoring disease activity and risks during pregnancies in women with systemic lupus erythematosus (SLE).
- Data from 532 lupus patients showed that complement levels generally rise during pregnancy but are notably lower in those with prior lupus nephritis and flares, particularly in the first trimester.
- Lower or minimal increases in C3 and C4 levels during early pregnancy were linked to higher rates of complications and gestational flares, suggesting these complement levels could help predict risks for SLE patients.
Article Synopsis
- The study focused on evaluating how patients with type 2 diabetes (T2D) intensified their treatment with basal insulin (BI) after being prescribed glucagon-like peptide-1 receptor agonists (GLP-1 RA) between 2011 and 2021.
- Out of 7,962 eligible patients, 39.7% initiated BI treatment, with most switching from GLP-1 RA, while others opted for add-ons or combination therapies.
- The findings emphasized the need to address clinical inertia in insulin treatment by using innovative therapy options to improve patient outcomes.
: Tofacitinib (TOFA) was the first Janus kinase inhibitor (JAKi) to be approved for the treatment of rheumatoid arthritis (RA). However, data on the retention rate of TOFA therapy are still far from definitive. : The goal of this study is to add new real-world data on the TOFA retention rate in a cohort of RA patients followed for a long period of time.
View Article and Find Full Text PDFArticle Synopsis
- A task force, including rheumatologists, healthcare professionals, and patients, was created to develop non-drug management recommendations for systemic lupus erythematosus (SLE) and systemic sclerosis (SSc) through a systematic literature review.
- They established 4 overarching principles and 12 tailored recommendations focused on patient education, physical activity, and lifestyle changes, with varying strengths of recommendation (A-D) and strong agreement among members.
- The goal is to enhance the holistic care of SLE and SSc, encouraging collaboration between patients and healthcare providers while integrating non-pharmacological strategies alongside traditional therapies.
Article Synopsis
- The study evaluated the effectiveness of belimumab for treating joint and skin symptoms in patients with systemic lupus erythematosus (SLE) using specific metrics like DAS28 and CLASI.
- Results showed notable improvements, with increasing percentages of patients achieving remission in joint (DAS28) and skin (CLASI) symptoms over 24 months.
- Belimumab was also found to reduce the need for glucocorticoids, and early responders (by 6 months) had a higher chance of achieving remission later in the treatment.
Objective: The major strengths of surgical treatment of benign prostatic hyperplasia with laser are reduced morbidity compared to endoscopic resection. No studies analysed the different risk of intra/peri-operative events between patients undergoing Thulium and GreenLight procedures.
Materials And Methods: We retrospectively reviewed 100 consecutive cases undergoing GreenLight vaporization and Thulium procedures performed during the learning curve of two expert endoscopic surgeons.
Background: Prospective data about the risks of thrombotic and severe haemorrhagic complications during pregnancy and post partum are unavailable for women with antiphospholipid syndrome. We aimed to assess thrombotic and haemorrhagic events in a prospective cohort of pregnant women with antiphospholipid syndrome.
Methods: This multicentre, prospective, observational study was done at 76 centres in France.
Introduction: Pivotal trials documented glycemic benefits of fixed-ratio combination of insulin glargine 100 U/mL and lixisenatide (iGlarLixi), with no weight gain and low hypoglycemia risk in type 2 diabetes (T2D). This study aimed at assessing effectiveness and patterns of use of iGlarLixi in a real-world setting.
Methods: This was a retrospective, multicenter, study, based on electronic medical records.
Objectives: To demonstrate that unsuccessful treatment optimization in early disease is associated with difficult-to-treat RA (D2T-RA).
Methods: In this retrospective multicentre cohort study conducted from 09/2021-03/2022, we enrolled individuals fulfilling the 2010 ACR/EULAR RA criteria diagnosed 2000-2019. The outcome was D2T-RA by the EULAR definition.
Background: The cysts of the male pelvic floor represent a rare clinical entity. Their origin is linked to an altered development of paramesonephric and mesonephric ducts during embryogenesis.
Case Presentation: We report our experience regarding two patients presenting cysts of the ejaculatory system treated with open and mini-invasive surgery.
Background And Aims: Data on second generation basal insulin (2BI) in people with type 2 diabetes (T2D) generated by clinical trials still need confirmation in real-world clinical settings. This study aimed at assessing the comparative effectiveness of 2BI [Glargine 300 U/mL (Gla-300) vs. Degludec 100 U/mL (Deg-100)] in T2D Italian patients switching from first generation basal insulins (1BI).
View Article and Find Full Text PDFAims: This study assessed comparative effectiveness of glargine 300 U/mL (Gla-300) versus degludec 100 U/mL (Deg-100) in insulin-naïve patients with T2D.
Methods: This is a retrospective, multicenter, non-inferiority study based on electronic medical records. All patients initiating Gla-300 or Deg-100 were 1:1 propensity score-matched (PSM).
Article Synopsis
- This study investigates whether low-dose acetylsalicylic acid (LDASA) should be given to pregnant patients with Systemic Lupus Erythematosus (SLE) who have no history of kidney issues or positive antiphospholipid antibodies.
- Researchers analyzed 216 pregnancies from 187 patients, comparing outcomes between those treated with LDASA and those who were not; they found no significant differences in adverse pregnancy outcomes (APOs) between the two groups.
- While LDASA treatment did show a lower incidence of pre-eclampsia (2.4% vs 8.3%), the overall conclusion is that LDASA does not significantly reduce severe obstetric complications,
Article Synopsis
- - The study aimed to assess the consensus among experts on defining antiphospholipid antibody (aPL) negativization in patients with antiphospholipid syndrome (APS) through a survey conducted by the Italian Society for Rheumatology (SIR-APS).
- - Results showed strong agreement (up to 90%) among a group of 30 experts on the definition of aPL negativization as having two negative tests one year apart, and on specific management approaches for patients with aPL negativity after experiencing thrombotic events.
- - Experts advised cautious suspension of vitamin K antagonists (VKAs) in patients with a history of thrombosis or triple aPL positivity, emphasizing that VKA cessation may be considered only when risks